Share on

Middle East and Africa Angina Pectoris Drugs Market Research Report – Segmented By Therapeutic Class & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: March, 2023
ID: 8027
Pages: 145
Formats: report pdf report excel report power bi report ppt

The MEA Angina Pectoris Drugs Market size is estimated to grow at a sluggish CAGR between 2022 and 2027.

Several reasons like physical exertion can cause angina, the growing geriatric and obese population, blocked arteries, emotional stress, cold, trauma, presence of coronary heart disease, diabetes, and hypertension, along with a family history of heart disease, smoking, etc. Therefore, the incidence of unstable angina is predicted to play an important role in the MEA angina pectoris drugs market, as the incidence rate is expected to experience healthy growth during the forecast period.

The increase in cases of heart disorders is boosting the market for pectoris angina drugs. The higher prevalence rate of angina drugs, easy availability of drugs and treatments, and continuous advancements in technology for diagnosis and treatment be responsible for driving this market.

According to the World Health Organization, the total number of people aged 65 and over is predicted to increase from 896 million in 2015 to around 1.55 billion in 2050. In 2017, more than 1.98 billion adults aged 18 and over were overweight. Of these, more than 660 million were obese. Approximately 39% of adults aged 18 and over were reported to be overweight, and around 13.23% were obese. In addition, overweight and obesity are killed at a higher frequency than more underweight people.

Other factors such as the research and development of effective drugs, the high demand for specific and suitable drugs for the treatment of angina pectoris, the introduction of new pharmacological agents, genomic drugs, and a growing trend towards strategic alliances and acquisitions are aiming to boost the MEA angina pectoris drugs market during the forecast period.

However, the high cost associated with cardiovascular surgeries and the time is taken to approve anti-angina drugs may hamper the MEA angina pectoris drug market.

This research report on the MEA angina pectoris drugs market has been segmented & sub-segmented into the following categories:

By Therapeutic Class:

  • Beta-Blockers     
  • Calcium Antagonists      
  • Anticoagulants    
  • Anti-Platelets     
  • Others    

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, Saudi Arabia and the United Arab Emirates are estimated to be the dominant share of the Middle Eastern market due to the high prevalence and increasing incidence rate of angina pectoris, large geriatric population, presence of good pharmaceutical companies, well-established health facilities, and growing awareness about cardiovascular disease and favorable medical reimbursement policies in these regions. Obesity and overweight are increasing rapidly in Saudi Arabia, with an overall high obesity prevalence of nearly 35.89%. Rising healthcare expenditure per capita and skilled labor will promote quality healthcare services, which are predicted to drive the growth of the angina treatment market in the Middle Eastern market in the years to come.

Patients in Africa and the Middle East have myocardial infarction at a much younger age, on average, compared to patients elsewhere. The projected future burden of coronary heart disease mortality in Africa and the Middle East exceeds that observed in other regions. Many African countries lack detailed and epidemiological data. The high proportions of expatriate workers passing through countries like Saudi Arabia and the United Arab Emirates complicate the construction of such data sets.  The African market is predicted to have slow growth regarding sales in the MEA angina pectoris market due to the growing prevalence of coronary heart disease and improving healthcare policies to elevate their infrastructure.

KEY MARKET PLAYERS:

Some of the major companies dominating the market by their products and services include Sanofi, Bayer HealthCare, Cardeus Pharmaceuticals and CardioVascular BioTherapeutics (CVBT), Merck & Co. Inc., Anthera Pharmaceuticals, Cardium Therapeutics, Astellas Pharma, Ark Therapeutics Group plc, Torrent Pharmaceuticals Limited, Circ Pharma Limited, HUYA Bioscience International LLC, Lacer S.A., Viromed Co. Ltd., and Baxter Healthcare Corporation.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample